Analysis on 1 500 adverse reactions of Guizhi Fuling Capsules based on spontaneous response system.
10.19540/j.cnki.cjcmm.20181219.001
- Author:
Rui-Li WEI
1
;
Yan-Ming XIE
1
;
Wen-Li ZHANG
2
Author Information
1. Institute of Basic Research in Clinical Medcine, China Academy of Chinese Medical Sciences Beijing 100700, China.
2. School of Statistics, Renmin University of China Beijing 100872, China.
- Publication Type:Journal Article
- Keywords:
Bayesian confidence propagation neural network;
Guizhi Fuling Capsules;
adverse drug reaction;
propensity score;
proportional reporting ratios;
spontaneous reporting system
- MeSH:
Adolescent;
Adult;
Adverse Drug Reaction Reporting Systems;
Bayes Theorem;
Capsules;
Drug-Related Side Effects and Adverse Reactions;
epidemiology;
Drugs, Chinese Herbal;
adverse effects;
Humans;
Risk Management;
Young Adult
- From:
China Journal of Chinese Materia Medica
2019;44(7):1497-1502
- CountryChina
- Language:Chinese
-
Abstract:
To understand the characteristics of adverse reactions and find early warning signs after intake of Guizhi Fuling Capsules. The 1 500 adverse reaction(ADR) cases of Guizhi Fuling Capsules obtained by spontaneous reporting system(SRS) from 2008 to 2017 were analyzed by proportional reporting ratios method(PRR), Bayesian confidence propagation neural network method(BCPNN) and propensity score method. The number of ADR reports increased year by year, and reached the peak in the fourth quarter of 2014. A total of 1 500 ADR cases were monitored, including 10 severe ADR cases. There were a total of 934 cases aged between 18-44 years old, accounting for 62.27%. All patients were orally administered. Among them, 1 398 patients received a single dose according to the package insert, and 57.4% had ADR within 24 h. The top five clinical manifestations of ADR were gastric dysfunction, abdominal pain, nausea, vomiting and rash, which mainly damaged the digestive system. The ADR signals were analyzed. PRR suggested that "gastric dysfunction" and "abdominal pain" were the early warning signals of Guizhi Fuling Capsules. BCPNN suggested that "nausea" and "abdominal pain" were the early warning signals of Guizhi Fuling Capsules. After the propensity score weighting method was used to control the confounding factors, the warning signals remained unchanged. The results show that Guizhi Fuling Capsules has fewer adverse reactions and is relatively safe. This study provides a basis for studying ADR of Guizhi Fuling Capsules, and guidance for drug vigilance and risk management of Guizhi Fuling Capsules.
